Clinical Trial Update: Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of nivolumab in recurrent/metastatic nasopharyngeal cancer completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-09-13